• BankM reiterated its Buy rating on Pentixapharm Holding on Nov. 4, 2026, with a 12-month price target of €11.51.
• PANDA Phase 3 enrollment is expected to begin in the first quarter of 2027, delayed from the second half of 2026.
• The expected 2026 loss narrowed to about €13 million from €21.6 million; funding remains sufficient into 2028.
• BankM shifted expected licensing upfront and initial milestone payments to 2027 from 2026, leaving amounts unchanged.
• The analyst retained its 2030 US market-entry assumption but flagged a possible delay to 2031.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pentixapharm Holding AG published the original content used to generate this news brief via EQS News (Ref. ID: rc_27304) on November 04, 2026, and is solely responsible for the information contained therein.